SHP Wealth Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$99.1K Sell
437
-5
-1% -$890 0.01% 413
2026
Q1
$76.2K Buy
442
+17
+4% +$3.15K 0.01% 425
2025
Q4
$84.8K Buy
+425
New +$77.1K 0.01% 385

Other funds holding CRL

SHP Wealth Management's CRL Position: Q2 2026 in Review

SHP Wealth Management reduced its Charles River Laboratories (CRL) stake by 1.1% in Q2 2026, selling an estimated $890 and leaving 437 shares worth $99.1K. The position accounts for 0.01% of the portfolio, ranked #413.

SHP Wealth Management first reported a position in CRL in Q4 2025 and has held it in 3 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • SHP Wealth Management held 437 shares of Charles River Laboratories worth $99.1K as of Q2 2026.
  • SHP Wealth Management sold 5 Charles River Laboratories shares in Q2 2026, an estimated $890.
  • Charles River Laboratories made up 0.01% of SHP Wealth Management's portfolio in Q2 2026, its #413 holding.
  • SHP Wealth Management first reported a position in Charles River Laboratories in Q4 2025 and has held it in 3 quarters since.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on SHP Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.